Abstract
The currently estimated number of genes in the human genome is much smaller than previously predicted. As an explanation for this disparity, most individual genes have multiple transcriptional units that represent a variety of biologically important gene products. GNAS exemplifies a gene of such complexity. One of its products is the α-subunit of the stimulatory heterotrimeric G protein (Gsα), a ubiquitous signaling protein essential for numerous different cellular responses. Loss-of-function and gain-of-function mutations within Gsα-coding GNAS exons are found in various human disorders, including Albrights hereditary osteodystrophy, pseudohypoparathyroidism, fibrous dysplasia of bone, and some tumors of different origin. While Gsα expression in most tissues is biallelic, paternal Gsα expression is silenced in a small number of tissues, playing an important role in the development of phenotypes associated with GNAS mutations. Additional products derived exclusively from the paternal GNAS allele include XLαs, a protein partially identical to Gsα, and two non-coding RNA molecules, the A/B transcript and the antisense transcript. The maternal GNAS allele leads to NESP55, a chromogranin-like neuroendocrine secretory protein. In vivo animal models have demonstrated the importance of each of the exclusively imprinted GNAS products in normal mammalian physiology. However, although one or more of these products are also disrupted by most naturally occurring GNAS mutations, their roles in disease pathogenesis remain unknown. To further our understanding of the significance of this gene in physiology and pathophysiology, it will be important to elucidate the cellular roles and the mechanisms regulating the expression of each GNAS product.
Keywords: GNAS antisense transcript, GTPase, NESP55, McCune-Albright Syndrome, Pseudohypoparathyroidism, Endocrine Adenomas
Current Genomics
Title: The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts
Volume: 8 Issue: 6
Author(s): Murat Bastepe
Affiliation:
Keywords: GNAS antisense transcript, GTPase, NESP55, McCune-Albright Syndrome, Pseudohypoparathyroidism, Endocrine Adenomas
Abstract: The currently estimated number of genes in the human genome is much smaller than previously predicted. As an explanation for this disparity, most individual genes have multiple transcriptional units that represent a variety of biologically important gene products. GNAS exemplifies a gene of such complexity. One of its products is the α-subunit of the stimulatory heterotrimeric G protein (Gsα), a ubiquitous signaling protein essential for numerous different cellular responses. Loss-of-function and gain-of-function mutations within Gsα-coding GNAS exons are found in various human disorders, including Albrights hereditary osteodystrophy, pseudohypoparathyroidism, fibrous dysplasia of bone, and some tumors of different origin. While Gsα expression in most tissues is biallelic, paternal Gsα expression is silenced in a small number of tissues, playing an important role in the development of phenotypes associated with GNAS mutations. Additional products derived exclusively from the paternal GNAS allele include XLαs, a protein partially identical to Gsα, and two non-coding RNA molecules, the A/B transcript and the antisense transcript. The maternal GNAS allele leads to NESP55, a chromogranin-like neuroendocrine secretory protein. In vivo animal models have demonstrated the importance of each of the exclusively imprinted GNAS products in normal mammalian physiology. However, although one or more of these products are also disrupted by most naturally occurring GNAS mutations, their roles in disease pathogenesis remain unknown. To further our understanding of the significance of this gene in physiology and pathophysiology, it will be important to elucidate the cellular roles and the mechanisms regulating the expression of each GNAS product.
Export Options
About this article
Cite this article as:
Bastepe Murat, The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts, Current Genomics 2007; 8 (6) . https://dx.doi.org/10.2174/138920207783406488
DOI https://dx.doi.org/10.2174/138920207783406488 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology An Update on Parkinson’s Disease and its Neurodegenerative Counterparts
Current Medicinal Chemistry Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology New Insights on Dimethylaminoethanol (DMAE) Features as a Free Radical Scavenger
Drug Metabolism Letters Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox
Current Pharmaceutical Design Neural Basis of Dental Pulp Stem Cells and its Potential Application in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
Current Drug Targets Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntingtons Disease
CNS & Neurological Disorders - Drug Targets The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Current Psychopharmacology An Update on Human Stem Cell-Based Therapy in Parkinson's Disease
Current Stem Cell Research & Therapy Emerging Biology of PDE10A
Current Pharmaceutical Design Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders